著者

今井 則博 池田 健次 瀬古 裕也 平川 美晴 川村 祐介 保坂 哲也 小林 正宏 斎藤 聡 瀬崎 ひとみ 芥田 憲夫 鈴木 文孝 鈴木 義之 荒瀬 康司 熊田 博光

出版者

一般社団法人 日本肝臓学会

雑誌

肝臓 (ISSN:04514203)

巻号頁・発行日

vol.51, no.12, pp.758-760, 2010 (Released:2010-12-29)

参考文献数

5

被引用文献数

3 2

---

Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting severe liver cirrhosis, there is no prospective data regarding clinical toxicity of miriplatin in HCC patients with severe cirrhosis. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 34 HCC patients with severe liver cirrhosis (Child-Pugh grade B). An anti-tumor effect of complete response was achieved in 8 of 34 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safety for HCC patients with Child-Pugh B liver cirrhosis.

著者

芥田 憲夫

出版者

科学評論社

雑誌

消化器内科 (ISSN:18842895)

巻号頁・発行日

vol.58, no.3, pp.342-348, 2014-03

著者

鈴木 義之 瀬崎 ひとみ 芥田 憲夫 鈴木 文孝 瀬古 裕也 今井 則博 平川 美晴 川村 祐介 保坂 哲也 小林 正宏 斎藤 聡 荒瀬 康司 池田 健次 小林 万利子 熊田 博光

出版者

一般社団法人 日本肝臓学会

雑誌

肝臓 (ISSN:04514203)

巻号頁・発行日

vol.52, no.2, pp.147-149, 2011 (Released:2011-03-22)

参考文献数

4

---

To further improve therapeutic effect on chronic hepatitis C, we have administered NS3 inhibitor and NS5A inhibitor together, and examined effects of early antiviral agent therapy. The subjects were five cases where interferon is ineffective (null responders). The NS5A and NS3 inhibitors are oral drugs and were daily administered for 24 weeks. Figure 1 shows time-dependent change of the number of viruses after the therapy started, and rapid decrease of viruses is recognized. Within 12 hours, HCV-RNA decreased by more than 2 log IU/ml in every patient. Two patients became negative for the virus by the 15th day after the therapy started. Furthermore, 80% of cases by the 28th day and all the cases by the 56th day became negative. The new therapy has manifested excellent early antiviral effect.

著者

芥田 憲夫 鈴木 文孝 川村 祐介 八辻 寛美 瀬崎 ひとみ 鈴木 義之 保坂 哲也 小林 正宏 小林 万利子 荒瀬 康司 池田 健次 熊田 博光

出版者

一般社団法人 日本肝臓学会

雑誌

肝臓 (ISSN:04514203)

巻号頁・発行日

vol.47, no.9, pp.450-451, 2006 (Released:2007-01-18)

参考文献数

5

被引用文献数

2 2

---

We evaluated 130 consecutive Japanese adults of HCV genotype 1b who received treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) for 48 weeks, to investigate the pretreatment predictive factors of early virologic response (EVR) and sustained virological response (SVR). 75% of patients could achieve EVR, and 45% were SVR. Multivariate analysis identified low density lipoprotein cholesterol (LDL-C) (≥86mg/dl) and amino acid (aa) substitutions in HCV core region (Double wild type; arginine at aa 70 and leucine at aa 91) as independent and significant determinants of EVR. Furthermore, multivariate analysis identified LDL-C (≥86mg/dl), aa substitutions in core region (Double wild type), gender (male), ICG R15 (<10%), AST (<60IU/l) as determinants of SVR. In conclusion, LDL-C and aa substitutions in core region are important pretreatment predictors of response to treatment with PEG-IFN plus RBV in Japanese patients infected with genotype 1b.